Nacralid (Naratriptan)

• Naratriptan belongs to the triptan class used to treat migraine and related headache disorders.
• Migraine attacks: provides rapid relief of headache, associated nausea, photophobia, phonophobia and other migraine symptoms, typically within two hours of dosing.
• Migraine with aura: reduces the intensity of visual or sensory aura phenomena and facilitates faster resolution of the subsequent headache phase.
• Adults who have not responded adequately to simple analgesics: offers a targeted serotonergic therapy that can abort an acute migraine episode when over‑the‑counter options fail.

• Naratriptan acts as a selective agonist at serotonin 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve endings. Activation of these receptors induces vasoconstriction of dilated intracranial arteries and inhibits the release of pro‑inflammatory neuropeptides, thereby interrupting the cascade that generates migraine pain and associated symptoms. The combined vascular and neuronal effects reduce peripheral sensitization and central pain transmission, leading to relief of the migraine attack.

Naratriptan may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Nausea
• Dizziness
• Dry mouth

Serious or Rare Side Effects

• Coronary vasospasm
• Serotonin syndrome
• Myocardial infarction

• Before prescribing naratriptan, clinicians should consider several precautionary measures to ensure patient safety.
• Assess cardiovascular history: patients with coronary artery disease, uncontrolled hypertension, or cerebrovascular disorders should be evaluated before use.
• Avoid concomitant ergot alkaloids: combined vasoconstrictive effects may increase risk of severe vascular events.
• Monitor serotonergic agents: use with SSRIs, SNRIs, or MAO inhibitors requires caution due to potential serotonin syndrome.
• Limit use in uncontrolled hypertension: elevated blood pressure may be exacerbated by the drug.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Naratriptan can interact with other medicines, and some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid)

• Ergot alkaloids: concurrent use may cause severe vasospasm and cardiovascular complications.
• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis when combined.
• Other triptans: additive vasoconstrictive effect increases cardiovascular risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise naratriptan plasma concentrations.

Moderate Interactions (Monitor Closely)

• SSRIs and SNRIs: combined use can increase the chance of serotonin syndrome; monitor for symptoms.
• Beta‑blockers: may elevate naratriptan levels, requiring dose adjustment.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug efficacy, consider alternative therapy.